


APR 7 2004



Substitute for form 1649A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	1	of	1	Application Number	10/634,641
				Filing Date	August 4, 2003
				First Named Inventor	TAKAHATA, KYOYA
				Art Unit	1614
				Examiner Name	N/A
				Attorney Docket Number	TECH-004

<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
	US-					
	US-					

<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					

<b>OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published				T <sup>2</sup>
<i>CM</i>		MORRE et al. "Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture" Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1831-1835, March 1995				
		TAKAHATA et al. "Growth Inhibition of capsaicin on hela cells is not mediated by intracellular calcium mobilization" Life Sciences, Vol. 64, No. 13, pp. PL 165-171 (1999)				
		SZALLASI et al. "Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor" Life Sciences Vol. 47, pp. 1399-1408 (1990)				
		MORRE et al. "Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines" European Journal of Cancer, Vol. 32A, No. 11, pp. 1995-2003, (1996)				

Examiner Signature	<i>CM</i>	Date Considered	9-29-04
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.